News
FDA Approves Bayer’s Sunharbo for Stroke Prevention
The first factor XIa inhibitor approved for secondary stroke prevention reduced the risk of ischaemic stroke by 26% when used alongside antiplatelet therapy in the Phase III OCEANIC-STROKE trial.
imphoenix82
- November 10, 2026
- 0 Comments
- 1.03K Views
-
